

9 Literaturverzeichnis

1. Allen TA, Polzin DJ, Adams LG. In MS Hand, CD Thatcher, RL Remillard, P Roudebush (Eds). Small Animal Clinical Nutrition, 4th edn. Topeka, Mark Morris Associates, 1999.
2. Lewis LD, Morris ML, Hand MS. In Klinische Diätetik für Hund und Katze, Schlütersche Verlagsanstalt und Druckerei, Hannover, 1990.
3. Peters H. Wirkungen der L-Arginingabe bei immunvermittelter akuter und chronischer Glomerulofibrose. Habilitationsschrift, V. Medizinische Klinik des Universitätsklinikums Charité, Humboldt Universität Berlin, 2000.
4. Finco DR, Brown SA, Barsanti JA, Bartges JW. Recent Developments in the management of progressive renal failure. Bonagura JD, ed.. Kirk's current veterinary therapy XIII. Small animal practice. W.B. Saunders Company, Philadelphia, Pennsylvania, 2000.
5. Nakamura T, Obata JE, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. *Kidney Int* 55:877-889, 1999.
6. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. *J Clin Invest* 90:766-771, 1992.
7. Kon R, Sugihara K, Tatematsu A, Fogo A. Internephron heterogeneity of growth factors and sclerosis: Modulation of platelet derived growth factor by angiotensin II: *Kidney Int* 47:131-139, 1995.
8. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H. Contribution of renal angiotensin type II receptor to gene expressions in hypertension-induced renal injury. *Kidney Int* 46:1346-1358, 1994.
9. Anderson S, Rennke HG, Brenner BM. Therapeutic advantages of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in rat. *J Clin Invest* 77:1999-2000, 1986.
10. Diamond JR, Anderson S. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis: Amelioration of angiotensin converting enzyme inhibition. *Am J Pathol* 137:1323-1332, 1990.

11. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Illis GW. Glomerular dynamics and morphology of aged spontaneously hypertensive rats: Effects of angiotensin converting enzyme inhibition. *Hypertension* 25:207-213, 1995.
12. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rats. *J Clin Invest* 85:541-549, 1990.
13. I-Hong Hsu S, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: A therapeutic role of complement inhibitors? *J Am Soc Nephrol* 14:S186-S191, 2003.
14. Barsanti JA. Urinary disorders. Kirk RW, Bonagura JD, ed.. *Kirk's current veterinary therapy XI. Small animal practice*. W.B. Saunders Company, Philadelphia, Pennsylvania, 1992.
15. Meyer TW, Rennke HG. Progressive glomerular injury following limited renal infarction in the rat. *Am J Physiol* 24:F858, 1988.
16. Shea SM, Raskova J, Morrison AB. Stereologic study of glomerular hypertrophy in the subtotally nephrectomized rat. *Am J Pathol* 90:201, 1978.
17. Brown SA, Navar LG. Single nephron responses to systemic administration of amino acids in dogs. *Am J Physiol* 258:F739, 1990.
18. Oberbauer R, Haas M, Mayer G. Proteinuria as a consequence of altered glomerular permselectivity-clinical implications. *Clin Nephrology* 46:357-361, 1996.
19. Braun N, Weber MH. Proteinurie bei fokal-segmentaler Glomerulosklerose. *Nieren Hochdruckkrh* 21:281-291, 1992.
20. Roche Lexikon Medizin, 4. erw. Auflage, Hrsg. v. Hoffmann-La Roche, Urban&Fischer Verlag, München, Deutschland, 1998.
21. Frank AE, Wingo CS, Weiner D. Effects of ammonia on bicarbonate transport in the cortical collecting duct. *Am J Physiol Renal Physiol* 278:F219-226, 2000.
22. Moslen MT. Free radicals in diagnostic medicine. Armstrong D, ed., Plenum Press, New York, 1994.
23. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. *Am J Med* 30:14S-22S, 1991.
24. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. *New Engl J Med*

- 12:1448-1456, 1998.
25. Thomas C..Histopathologie. 13. Auflage, Hrsg. Thomas C., Schattauer Verlag, Stuttgart, Deutschland, 2001.
 26. Schöklmann H, Lang S, Sterzel B. Regulation of mesangial cell proliferation. *Kidney Int* 56:1199-1207, 1999.
 27. Pabst R, Sterzel RTB. Cell renewal of glomerular cell types in normal rats: An autoradiographic analysis. *Kidney Int* 24:626-631, 1983.
 28. Sherr CJ. D-type cyclins. *Trends Biochem Sci* 20 :187-190, 1995.
 29. Shankland SJ, Pippin J, Flanagan M, Coats SR, Nangaku M, Gordon KL, Roberts JM, Couser WG, Johnson RJ. Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. *Kidney Int* 51:1088-99, 1997.
 30. Pesce CM, Striker LJ, Peten E, Elliot SJ, Striker GE. Glomerulosclerosis at both early and late stages is associated with increased cell turnover in mice transgenic of growth hormone. *Lab Invest* 65:601-605, 1992.
 31. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the rat remnant kidney model. *Kidney Int* 41:297-309, 1992.
 32. Pippin JW, Qu Q, Meijer L, Shankland SJ. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. *J Clin Invest* 15:2512-20, 1997.
 33. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? *Kidney Int* 54:687-697, 1998.
 34. Pavenstädt H. Roles of podocytes in glomerular function. *Am J Renal Physiol* 278:F173-179, 2000.
 35. Gordon S. Macrophages and the immune system. *Fundamental Immunology*, 4th Ed.. Paul WE, ed., Lippincott-Raven Publishers, Philadelphia, 1999.
 36. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage receptor activity: a marker of alternative immunologic macrophage activation. *J Exp Med* 176:287-92, 1992.

37. Duffield JS. The inflammatory macrophage: a story of Jekyll and Hyde. *Clin Sci* 104:27-38, 2003.
38. Gordon S. Alternative activation of macrophages. *Nat Rev Immunol* 1:23-35, 2003.
39. Rennke HG, Klein PS, Sandstrom DJ. Cell-mediated immune injury in the kidney: Acute nephritis induced in the rat by azobenzeneearsonate. *Kidney Int* 45:1044-1056, 1994.
40. Alexopoulos E, Seron D, Hartley RB. Luplus nephritis: Correlation of interstitial cells with glomerular function. *Kidney Int* 37:100-109, 1990.
41. Huang XR, Tipping PG, Apostopoulos J, Oettinger C, D'Souza M, Milton G, Holdsworth SR. Mechanisms of T-cell induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats. *Clin Exp Immunol* 109:134-142, 1997.
42. Penny MJ, Boyd RA, Hall BM. Role of t cells in mediation of Heymann nephritis. II. Identification of Th1 and cytotoxic cells in glomeruli. *Kidney Int* 51:1059-1068, 1997.
43. Kawasaki K, Yaoita E, Yamamoto T, Kihara I. Depletion of CD8 positive cells in nephrotoxic serum nephritis in WKY rats. *Kidney Int* 41:1517-1526, 1992.
44. Lakkis FG; baddoura FK, Cruet EN, Parekh KR, Fukunaga M, Munger KA. Anti-inflammatory lymphokine in mRNA expression in antibody-induced glomerulonephritis. *Kidney Int* 49:117-126, 1996.
45. Lan HY, Paterson DJ, Atkins RC. Initiation and evolution of interstitial leukocytic infiltration in experimental glomerulonephritis. *Kidney Int* 40:425-433, 1991.
46. Kreisberg JI, Wayne DB, Karnovsky MJ. Rapid and focal loss of negative charge associated with mononuclear cell infiltration early in nephrotoxic serum nephritis. *Kidney Int* 16:290-300, 1979.
47. Main W, Nikolic-Paterson DJ, Atkins RC. T cells and macrophages and their role in renal injury. *Sem Nephrology* 12:395-407, 1992.
48. Wofsy C, Coombs D, Goldstein B. Calculations show substantial serial engagement of T cell receptors. *Biophys J* 80:606-612, 2001.
49. Griffiths GM, Mueller C. Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells. *Immunol Today* 12:415-419, 1991.
50. Krähenbuhl O, Tschopp J. Perforin-induced pore formation. *Immunol Today* 12:399-

- 402, 1991.
51. Roit I, Brostoff J, Male D. Immunology. 5th Ed. Elsevier-Mosby, pp 85-92 & 353-365, 1998.
52. Stryer L. Biochemie. 4. Auflage, Heidelberg, Spektrum Akad. Verlag, 1996.
53. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM. Two-step binding mechanism for T-cell receptorrecognition of peptide MHC. Nature 418:552-6, 2002.
54. Loppnow H. Zytokine: Klassifikation, Rezeptoren, Wirkungsmechanismen. Internist 42:13-27, 2001.
55. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF- β activation. J Cell Science 116:217-224, 2003.
56. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 15:1349-65, 1999.
57. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast conditioned medium. J Cell Biol 106:1659-65, 1988.
58. Ashcroft GS, Yang X, Glich AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild, Wahl SM, Deng C, Roberts AB. Mice lacking Smad 3 show accelerated wound healing and impaired local inflammatory response. Nat Cell Biol 5:260-266, 1999.
59. Shi Y, Massgue J, Thomas L. Mechanisms of TGF- β signaling from cell membrane to the nucleus. Cell 113:685-700, 2003.
60. Reinhold D. Transforming growth factor- β (TGF- β) – eine kurze Einführung. Symposium TGF- β in Forschung und Diagnostik. Abstractband, Magdeburg, 2001.
61. Moses HL, Yng EY, Pictenpol JA. TGF- β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63:245-247, 1990.
62. Wahl SM, Hunt DA, Wakefield LM. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 16:5788-92, 1987.
63. Ballermann BJ, Dardik A, Eng E, Liu A. Shear stress and the endothelium. Kidney Int 67:S100-8, 1998.
64. Zhang SL, To C, Chen X, Filep JG, Tang SS, Inselfinger JR, Chan JS. Essential role(s) of the intrarenal rennin-angiotensin system in transforming growth factor-beta1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in

- high glucose. *J Am Soc Nephrol* 13:302-12, 2002.
65. Fraser D, Wakefield L, Phillips A. Independent regulation of transforming growth factor-beta1 transcription and translation by glucose and platelet-derived growth factor. *Am J Pathol* 161:1039-49, 2002.
66. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. *Kidney Int* 56:393-405, 1999.
67. Wolf G, Jocks T, Zahner G, Panzer U, Stahl RA. Existence of a regulatory loop between MCP-1 and TGF-beta in glomerular immune injury. *Am J Renal Physiol* 283:F1075-84, 2002.
68. Reddi AS, Bollineni JS. Selenium-deficient diet induces renal oxidative stress and injury via TGF-beta1 in normal and diabetic rats. *Kidney Int* 59:1342-53, 2001.
69. Sahai A, Mei C, Schrier RW, Tannen RI. Mechanisms of chronic hypoxia-induced renal cell growth. *Kidney Int* 56(4):1277-81, 1999.
70. Wilcox CS, Welch WJ. Interaction between nitric oxide and oxygen radicals in regulation of tubuloglomerular feedback. *Acta Physiol Scand* 168(1):119-24, 2000.
71. Lopez-Armada MJ, Gomez-Guerrero C, Egido J. Receptors for immune complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: role of TGF-beta. *J Immunol* 157(5):2136-42, 1996.
72. Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. *Kidney Int* 6:1497-510, 1997.
73. O'Donnell. Renal tubulointerstitial fibrosis: new thoughts on its development and progression. *Postgrad Med* 108(1):159-72, 2000.
74. Thibault G, Lacombe M-J, Schnapp LM, Lacasse A, Bouzeghrane F, Lapalme G. Upregulation of $\alpha_8\beta_1$ -integrin in cardiac fibroblasts by angiotensin II and transforming growth factor β . *Am J Physiol Cell Physiol* 281:C1457-C1467, 2001.
75. De Gasparo M, Bottari S, Levens NR. Characteristics of angiotensin II receptors and their role in cell and organ physiology. In JH Laragh, BM Brenner (eds). *Hypertension: Pathophysiology, Diagnosis and Management* (ed 2). New York, NY, Raven, 1995.
76. Silbernagel, Despopoulos. *Taschenatlas der Physiologie*. 5. Auflage. Georg Thieme Verlag KG, Stuttgart, New York, 2001.

77. Broome M, Haney M, Osterlund B, Haggmark S, Johansson G, Biber B. Cardiac effects of intracoronary angiotensin II infusion. *Anesth Analog* 94:787-93, 2002.
78. Cody RJ. Angiotensin II-mediated vasoconstriction in chronic congestive heart failure, and response to converting enzyme inhibition. *Am J Med* 77(2A):71-7, 1984.
79. Ardaillou R, Chansel D. Glomerular effects of Angiotensin II: a reappraisal based on studies with non-peptide receptor antagonists. *J Hypertension* 11(S):S43-47, 1993.
80. Navar LG, Kobori H, Pietro-Carrasquero M. Intrarenal angiotensin II and hypertension. *Hypertens Rep* 5:135-43, 2003.
81. Breidert M, Bornstein SK, Ehrhart-Bornstein M, Scherbaum WA, Holst JJ. Angiotensin II regulates both adrenocortical and adrenomedullary function in isolated perfused pig adrenals. *Peptides* 17:287-92, 1996.
82. Kim NN, Villarreal FJ, Printz MP, Lee AA, Dillmann WH. Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. *Am J Physiol* 269:E426-37, 1995.
83. Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. *Hypertension* 44:195-202, 2004.
84. Zitnay C, Siragy HM. Action of angiotensin receptor subtypes on the renal vasculature: Implications for volume homeostasis and atherosclerosis. *Miner Electrolyte Metab* 24:362-370, 1998.
85. Dzau VJ, Sasmura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications. *Hypertension* 11 [Suppl 3]:S13-18, 1993.
86. Siragy HM, Howell NL, Rasdale NV, Carey RM. Renal interstitial fluid angiotensin. Modulation anesthesia, epinephrine, sodium depletion and rennin inhibition. *Hypertension* 25:1012-24, 1995.
87. Sechi LA, Grady EF, Griffin CA, Kalinyak JE, Schambellan M. Distribution of angiotensin II receptor subtypes in rat and human kidney. *Am J Physiol* 262:F236-F240, 1992.
88. Zitnay C, Siragy HM. Action of angiotensin receptor subtypes on the renal vasculature: Implications for volume homeostasis and atherosclerosis. *Miner Electrolyte Metab* 24:362-370, 1998.

89. Siragy HM. AT1 and AT2 receptors in the kidney: Role in disease and treatment. *Am J Kidney Dis* 36 [Suppl 1]:S4-9, 2000.
90. Hunyady L, Balla T, Catt KJ. The ligand binding site of the angiotensin AT1 receptor. *Trend Pharmacol Sci* 17:135-140, 1996.
91. Horiuchi M, Ashita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. *Hypertension* 33:613-621, 1999.
92. Kiron MA, Soffer RL. Purification and properties of a soluble angiotensin II-binding protein from rabbit liver. *J Biol Chem* 264:4138-4142, 1989.
93. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. *Cell* 75:977-984, 1993.
94. Mercure C, Ramla D, Garcia R, Thibault G, Deschepper CF, Reudelhuber TL. Evidence for intracellular generation of angiotensin II in rat juxtaglomerular cells. *FEBS Lett* 422:395-399, 1998.
95. De Mello WC. Renin-angiotensin system and cell communication in failing heart. *Hypertension* 27:1267-1272, 1996.
96. Haller H, Lindschau C, Erdmann B, Quass P, Luft FC. Effects of intracellular angiotensin II in vascular smooth muscle cells. *Circ Res* 79:765-772, 1996.
97. Haller H, Lindschau C, Quass P, Luft FC. Intracellular actions of angiotensin II in vascular smooth muscle cells. *J Am Soc Nephrol [Suppl 1]:S75-83*, 1999.
98. Brailoui E, Filipeanu CM, Tica A, Toma CP, de Zeeuw D, Nelemans SA. Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta. *Br. J Pharmacol* 126:1133-1138, 1999.
99. Jefferson JA, Johnson RJ. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). *J Nephrol* 12:297-307, 1999.
100. Singer AJ, Clark RA. Cutaneous wound healing. *N Engl J Med* 341:738-46, 1999.
101. Carvalho-Pinto CE, Garcia MI, Mellado M, Rodriguez-Frade JM, Matin-Caballero J, Flores J, Martinez-A C, Balomenos D. Autocrine production of IFN- γ by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. *J Immunol* 169, 2002.
102. Tam FW. Role of selectins in glomerulonephritis. *Clin Exp Immunol* 129:1-3,

- 2002.
103. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. *Biochem J* 113:515, 1969.
 104. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficiency and safety. *J Am Acad Dermatol* 17:962-967, 1987.
 105. Allison AC, Eugui EM. Mycophenolate mofetil, a rationally designed immunosuppressive drug. *Clin Transplant* 7:96-112, 1993.
 106. Yashima Y, Ohgane T. Pharmacological profile of mycophenolate mofetil (CellCept), a new immunosuppressive agent. *Nippon Yakurigaku Zasshi* 117:131-137, 2001.
 107. Pirsch JD, Sollinger HW. Mycophenolate mofetil-clinical and experimental experience. *Ther Drug Monit* 18:357-361, 1996.
 108. European Mycophenolate Mofetil Cooperative Study Group. A placebo-controlled study of mycophenolate mofetil used in combination with cyclosporin and corticosteroids for the prevention of acute renal allograft recipients. *Lancet* 345:1321-1325, 1995.
 109. Sollinger HW. Mycophenolate mofetil. *Kidney Int [Suppl]* 52:S14-17, 1995.
 110. Halloran PF, Mathers T, Tomplanovitch S, Groth C, Hooftmann GL, Barker C for the International MMF Renal Transplant Study Group. Mycophenolate mofetil in renal allograft recipients, a pooled analysis of three randomized, double-blind, clinical studies in prevention of rejection. *Transplantation* 63:39-47, 1997.
 111. Kiberd B, MacDonald A. Mycophenolate and glomerular disease. *Am J Kidney Dis* 31:364-365, 1998.
 112. Lee WA, Gu L, Mkisztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. *Pharm Res* 7:161-166, 1990.
 113. Warren SE, O'Connor DT. Hyperkalemia resulting from captopril administration. *JAMA* 244:2551-2552, 1980.
 114. Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamics and pharmacokinetic properties and clinical efficacy in renal transplantation. *Drugs* 51:278-298, 1996.

115. Bullingham R, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS 61443). A short review. *Transplant Proc* 28:925-929, 1996.
116. Allison Ac, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. *Springer Sem Immunopathol* 14:353-380, 1999.
117. Brown NJ, Vaughan DE. Angiotensin converting enzyme inhibitors. *Circulatio* 97:1411-1420, 1998.
118. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. *J AM Soc Nephrol* 10:1542-1549, 1999.
119. Peters H, Border WA, Noble NA. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. *Kidney Int* 57:1493-1501, 2000.
120. Sponer G. In Frey H-H, Löscher W (Eds.). *Lehrbuch der Pharmakologie und Toxikologie für die Veterinärmedizin*, p 2354-235. Stuttgart, Ferdinand Enke Verlag, 1996.
121. Peters H, Border WA, Noble NA. Targeting TGF- β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. *Kidney Int* 54-1570-1580, 1998.
122. Ribeiro W, Muscará MN, Martins AR, Moreno H, Mendes GB, De Nucci G. Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. *Eur J CLn Pharmacol* 50:399-405, 1996.
123. MacFayden RJ, Meredith PA, Elliot HL. Enalapril mclinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. *Clin Pharmacokinet* 25:274-282, 1993.
124. Hodsmen GP, Isles CG, Murray GD, Usherwood TP, Webb I, Robertson JI. Factors related to first dose hypotensive effect of captopril: prediction and treatment. *BMJ* 286:832-834, 1983.
125. Warren SE, O'Connor DT. Hyperkalemia resulting from captopril administration. *JAMA* 244:2551-2552, 1980.
126. Nakayama H, Oite T, Kawachi H, Morioka T, Kobayshi H, Orikasawa M, Arakawa M, Shimizu F. Comparative Nephritogenicity of two monoclonal antibodies that recognize different epitopes of rat Thy1.1 molecule. *Nephron* 78:453-463, 1998.

127. Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Ohashi R, Sugisaki Y, Yamanaka N. Complement-mediated killing of mesangial cells in experimental glomerulonephritis: Cell death by a combined apoptosis and necrosis. *Nephron* 86:152-160, 2000.
128. Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG. Enzyme-linked immunoassay (ELISA) for connective tissue components. *Anal Biochem* 104:205-214, 1980.
129. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. *N Engl J Med* 318:1657-1666, 1988.
130. Wu JC,. Mycophenolate mofetil olecular mechanisms of action. *Perspect Drug Discovery Des* 2:185-204, 1994.
131. Sintchak MD, Fleming MA, Futer O. Structure and mechanisms of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. *Cell* 85:921-930, 1996.
132. Schnülle P, Van Der Woude FJ. Mycophenolat Mofetil im Vergleich zu anderen Immunsuppressiva. *Internist* 39:879-886, 1998.
133. Halloran PF. Molecular mechanisms of new immunosuppressants. *Clin Transplant* 10:118-123, 1996.
134. Eugui EM, Mirkovich A, Allison AC. Lymphocyte selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholenoethylester (RS-61443) in rodents. *Transplant Proc* 23 [Suppl 2]:S15-18, 1991.
135. Wang Y, Krämer S, Loof T, Martini S, Kron S, Neumayer HH, Shimizu F, Kawachi H, Peters H. Stimulation of soluble guanylate cyclase slows progression in chronic anti-thy1 glomerulosclerosis. *Kidney Int* 68:47-61, 2005.
136. Krämer S, Loof T, Martini R, Rückert M, Wang Y, Böhler T, Shimizu F, Kawachi H, Neumayer HH, Peters H. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis, but is not additive to a high dose of enalapril. *Am J Physiol Renal Physiol* 289:F359-368, 2005.
137. Wang Y, Krämer S, Loof T, Martini S, Kron S, Shimizu F, Kawachi H, Neumayer HH, Peters H. Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation versus phosphodiesterase inhibition. *Am J Physiol Renal Physiol* 290:F167-76, 2006.

138. Van Vliet A, Balde HJ, Vleming HJ, de Heer E, Bruijn JA. Distribution of fibronectin isoforms in human renal disease. *J Pathol* 93:256-62, 2001.
139. Johannson S, Svineng G, Wennerberg K, Armulik A, Lohikangas L. Fibronectin-Integrin-Interactions. *Front Bioscience* 2:d126-46, 1997.
140. Massey RC, Kantzanou MN, Fowler T, Day NP, Schofield K, Wann ER, Berendt AR, Hook M, Peacock SJ. Fibronectin-binding protein A of *Staphylococcus aureus* has multiple, substituting, binding regions that mediate adherence to fibronectin and invasion of endothelial cells. *Cell Microbiol* 3: 839-51, 2001.
141. Blum S, Hug F, Hansch GM, Wagner C. Fibronectin on activated T-lymphocytes is bound to gangliosides and is present in detergent insoluble microdomains. *Immunol Cell Biol* 83:167-74, 2005.
142. Mould AP, Akiyama SK, Humphries MJ. Regulation of integrin $\alpha 5 \beta 1$ -fibronectin interactions by divalent cations. Evidence of distinct classes of binding sites for Mn^{2+} , Mg^{2+} and Ca^{2+} . *J Biol Chem* 270:26270-7, 1995.
143. Mosher TF, Sottile J, Wu C, McDonald JA. Assembly of extracellular matrix. *Curr Opin Cell Biol* 4:810-8, 1992.
144. Song C-Z, Tian X, Gelehrter TD. Glucocorticoid receptor inhibits transforming growth factor- β signaling by directly targeting the transcriptional function of Smad3. *Proc Natl Acad Sci* 96:111776-11781, 1999.
145. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. *Am J Pathol* 148:1345-1350, 1996.
146. Rondeau E, Sraer JD, Schleuning WD. The renal plasminogen activating system. In D Schlondorff, JV Bonventre (eds). *Molecular Nephrology: Kidney Function in Health and Diseases*. Marcel Dekker Inc., New York, 1995.
147. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. *Kidney Int* 58:1841-1850, 2000.
148. Basile DP. Is angiotensin II's role in fibrosis as easy as PAI(-1)? *Kidney Int* 58:460-461, 2000.
149. Dennler H, Itoh S, Vivien D, Dijke P, Huet S, Gauthier JM. Direct binding of smad 3 and smad4 to critical TGF β -inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J* 17:3091-3100, 1998.

150. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. *Kidney Int* 58:251-259, 2000.
151. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin converting enzyme inhibition suppresses plasminogen activator inhibition-1 expression in the neointima of balloon-injured rat aorta. *Circulation* 93:1073-1078, 1996.
152. Oikawa T, Freeman M, Lo W, Vaughan DE. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the antifibrotic effect of renin-angiotensin inhibition. *Kidney Int* 51:161-172, 1997.
153. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA. Dual effects of angiotensin II on the plasminogen/ plasmin system in the rat mesangial cell. *Kidney Int* 51:664-671, 1997.
154. Peters H, Border WA, Rückert M, Krämer S, Neumayer HH, Noble NA. L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. *Kidney Int* 63:1382-1392, 2003.
155. Zatz R, Noronha IL, Fujihara CK. Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies. *Am J Physiol Renal Physiol* 283:F1167-1175, 2002.
156. Wada Y, Morioka T, Oyanagi-Tanaka Y, Yao J, Suzuki Y, Gejyo F, Arakawa M, Oite T. Impairment of vascular regeneration precedes progressive glomerulosclerosis in anti-thy1 glomerulonephritis. *Kidney Int* 61:432-443, 2002.
157. Fujihara CK, Lourdes-Noronha I, Malheiros I, Antunes GR, de Oliveira IB, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. *J Am Soc Nephrol* 11:283-290, 2000.
158. Yang CW, Ahn HJ, Kim WY, Li C, Jung JY, Yoon SA, Kim YS, Cha JH, Kim J, Bang BK. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. *Transplantation* 75:309-315, 2003.
159. Vesey DA, Cheung C, Cuttle L, Endre Z, Gobe G, Johnson DW. Interleukin 1beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-beta –dependant mechanism. *J Lab Clin Invest* 140:342-350, 2002.
160. Phillips AO, Topley mN, Steadman R, Morrissey K, William JD. Induction of TGF-beta1 synthesis in D-glucose primed human proximal tubular cells by IL-1 beta and

- TNF-alpha. *Kidney Int* 50:1546-1554, 1996.
161. Fan JM, Huang XR, Ng YY, Nikolic-Patterson DJ, Mu W, Atkins RC, Lan HY. Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-beta1-dependant mechanism in vitro. *Am J Kidney Dis* 37:820-831, 2001.
162. Rovin BH, Tan LC. Role of protein kinase pathways in IL-1-induced chemoattractant expression by human mesangial cells. *Kidney Int* 46:1059-1068, 1994.
163. Uciechowski P, Saklavalala J, der-Ohe J, Resch K, Szamel M, Kracht M. Interleukin 1 activates jun N-terminal kinases JNK1 and JNK2 but not extracellular regulated MAP kinase (ERK) in human glomerular mesangial cells. *FEBS Lett* 394:273-278, 1996.
164. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Varenterghem Yf. Mycophenolate mofetil in IgA nephropathy: >Results of a 3-year prospective placebo-controlled randomized study. *Kidney Int* 65:1842-1849, 2004.